There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM – Research Report) and Evolent Health (EVH – Research Report) with bullish sentiments.
Dexcom (DXCM)
Canaccord Genuity analyst William Plovanic maintained a Buy rating on Dexcom yesterday and set a price target of $137.00. The company’s shares closed last Monday at $129.63, close to its 52-week high of $139.55.
According to TipRanks.com, Plovanic is a 1-star analyst with an average return of
Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $135.13, representing a 7.5% upside. In a report issued on January 3, BTIG also maintained a Buy rating on the stock with a $150.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Evolent Health (EVH)
Canaccord Genuity analyst Richard Close maintained a Buy rating on Evolent Health yesterday and set a price target of $47.00. The company’s shares closed last Monday at $32.70.
According to TipRanks.com, Close is a 5-star analyst with an average return of
Evolent Health has an analyst consensus of Strong Buy, with a price target consensus of $43.78, a 35.3% upside from current levels. In a report issued on January 2, Barclays also initiated coverage with a Buy rating on the stock with a $39.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DXCM:
- DexCom price target raised to $150 from $125 at BTIG
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/2/2024
- DexCom participates in a conference call with William Blair
- William Blair says buy these stocks for 2024
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
